Surgery is usually the only solution to modify the evolution of morbid obesity and resolve the associated co-morbidities. There is very little written regarding malabsorptive surgery and transplantation. A 48-yearold male with hypertension, hyperuricemia and obesity underwent renal transplantation in 1994 for renal amyloidosis. He was maintained on oral immunosuppressive cyclosporine. The patient developed uncontrollable hypertension, hyperlipemia, hyperglycemia and increasing weight to a BMI of 44. Thus, in December 2004, he underwent biliopancreatic diversion (BPD). After 18 months follow-up, he has lost 85% of his excess weight, and his hypertension, hyperglycemia and hyperlipemia are markedly improved. Renal function was not modified, nor were the levels of cyclosporine. He has had no complications derived from the BPD, and has a better quality of life.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Scopinaro N. Biliopancreatic diversion: mechanisms of action and long-term results. Obes Surg 2006; 16: 683–.
Scopinaro N, Marinari GM, Camerini GB et al. Specific effects of biliopancreatic diversion on the major components of metabolic syndrome: a long-term follow-up study. Diabetes Care 2005; 28: 2406–1.
Adami G, Murelli F, Carlini F et al. Long-term effect of biliopancreatic diversion on blood pressure in hypertensive obese patients. Am J Hypertens 2005; 18: 780–.
Ducloux D, Kazory A, Simula-Faivre D et al. Oneyear post-transplant weight gain is a risk factor for graft loss. Am J Transplant 2005; 5: 2922–.
Kramer HJ, Saranathan A, Luke A et al. Increasing body mass index and obesity in the incident ESRD population. J Am Soc Nephrol 2006; 17: 1453–.
Bach JF. Lessons for transplant immunosuppression from the usage of cyclosporine in autoimmune diseases. Transplant Proc 1994; 36: 3077–1.
Armstrong KA, Campbell SB, Hawley CM et al. Obesity is associated with worsening cardiovascular risk factor profiles and proteinuria progression in renal transplant recipients. Am J Transplant 2005; 5: 2710–.
Hanish SI, Petersen RP, Collins BH et al. Obesity predicts increased overall complications following pancreas transplantation. Transplant Proc 2005; 37: 3564–.
Cofan F, Vela E, Cleries M. Obesity in renal transplantation: analysis of 2691 patients. Transplant Proc 2005; 37: 3695–.
Gore JL, Pham PT, Danovitch GM et al. Obesity and outcome following renal transplantation. Am J Transplant 2006; 6: 357–3.
Hibberd AD, Trevillian PR, Roger SD et al. Assessment of the bioequivalence of a generic cyclosporine A by a randomized controlled trial in stable renal recipients Transplantation 2006; 15; 81: 711–.
Kasap B, Soylu A, Turkmen M et al. Effect of obesity and overweight on cyclosporine blood levels and renal functions in renal adolescent recipients. Transplant Proc 2006; 38: 463–.
Ablassmaier B, Klaua S, Jacobi CA et al. Laparoscopic gastric banding after heart transplantation. Obes Surg 2002; 12: 412–.
Weiss H, Nehoda H, Labeck B et al. Organ transplantation and obesity: evaluation, risks and benefits of therapeutic strategy. Obes Surg 2000; 10: 465–.
Newcombe V, Blanch A, Slater GH et al. Laparoscopic adjustable gastric banding prior to renal transplantation. Obes Surg 2005; 15: 567–0.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Deogracias, M.L., Domínguez-Diez, A., Palomar-Fontanet, R. et al. Biliopancreatic Diversion in a Renal Transplant Patient. OBES SURG 17, 553–555 (2007). https://doi.org/10.1007/s11695-007-9097-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-007-9097-z